Mike would be a good captain to steer the ship of commercialisation from Day 1. If he were there since DX CE approval, TK and his team would be able to focus on technical matters, and so on other lame Sanofi MB BS would be chopped off by him giving way to government/clinic contact. Don’t be surprised if he can perform as short as 1-3 month, as he sounds like pretty switched. First thing first he agreed with RAP is a listed company you have to care for the return for all shareholders. Bring it back to teens 2021!
RAP Price at posting:
7.8¢ Sentiment: Buy Disclosure: Held
